Sanjay Shete
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (23)
Year:
2026
Year:
2026
Background: Alcohol, a known carcinogen since 1988, increases risk of cancers of the mouth, pharynx, larynx, esophagus, liver, breast, and colorectum. More than one half of US adults consume alcohol whereas about two thirds are unsure whether or unaware that alcohol intake is linked to cancer risk. Methods: Our objective was to survey awareness, beliefs, intentions, policies, practices, and goals/perceived responsibilities related to establishing/promoting actions to reduce alcohol-related cancer risks from leaders of 72 NCI-Designated Cancer Centers. Results: Sixty-one percent responded. Forty-three percent either believed in or were uncertain about alcohol’s purported health benefits. Nevertheless, 86% considered it part of their job to warn the public about alcohol’s carcinogenic effects. Fifty-two percent had at least one alcohol-related policy in place; among that subset, 83% had a policy related to alcohol service during on-site events; 87% had one about reimbursement of that alcohol service. Of concern, only 45% of survey respondents agreed that current literature with regard to alcohol-related cancer risk factors was sufficient to warrant a reconsideration of their alcohol-related policies/practices, and fewer than half have acted on those data. Conclusions: NCI-Designated Cancer Centers can implement policies and change practices now to reduce alcohol intake and the cancer deaths associated with its consumption. Impact: Cancer centers’ leadership in alcohol practices and policies may energize the public to be more thoughtful about their use of alcohol, resulting in long-term reductions in associated cancer risks. See related In the Spotlight, p. 190
Year:
2026
Background Low-flow supplemental oxygen (LFSO), high-flow nasal cannula (HFNC), and non-invasive ventilation (NIV) are often used for palliation of dyspnea in hospitalized patients. However, it is unclear how patients prefer to use these modalities and how they can be personalized for optimal dyspnea relief. The objective of this randomized clinical trial is to compare the effect of a personalized respiratory therapist (RT)-led intervention, termed SPOT-ON, and enhanced usual care on dyspnea intensity in both hypoxemic and non-hypoxemic hospitalized patients with cancer. Methods In this two-arm, parallel group, partially blinded, waitlist-controlled randomized clinical trial, hospitalized patients with advanced cancer and at least moderate dyspnea intensity at rest (numeric rating scale [NRS] ≥4/10) will be randomized 1:1 to receive SPOT-ON immediately or after a 72-hour waiting period. The SPOT-ON intervention consists of a time-limited trial of LFSO, HFNC, and NIV for 10 minutes each, followed by personalized deployment of these modalities to tailor device settings and timing and duration of use based on patient preference over 72 hours. The waitlist control group will receive structured dyspnea education after enrollment and usual care. The primary outcome will be change in dyspnea NRS intensity from baseline to 24 hours. Secondary outcomes include dyspnea unpleasantness, vital signs, symptom burden, health-related quality of life, adverse events, pattern of device use, and hospital outcomes. We calculated that 150 patients (75 hypoxemic and 75 non-hypoxemic) will provide 80% power to detect a 1.2-point difference between groups with α = 0.025, assuming a standard deviation of 1.5 and 20% attrition. Discussion Successful completion of this clinical trial could inform the use of oxygen and supportive modalities to reduce dyspnea. This novel personalized clinical trial methodology involving time-limited trials to tailor therapy based on patient preferences may inform the design of future supportive care clinical trials. Trial registration Clinicaltrials.gov NCT06336642
Year:
2025
Background: Alcohol, a known carcinogen since 1988, increases risk of cancers of the mouth, pharynx, larynx, esophagus, liver, breast, and colorectum. More than one half of US adults consume alcohol whereas about two thirds are unsure whether or unaware that alcohol intake is linked to cancer risk. Methods: Our objective was to survey awareness, beliefs, intentions, policies, practices, and goals/perceived responsibilities related to establishing/promoting actions to reduce alcohol-related cancer risks from leaders of 72 NCI-Designated Cancer Centers. Results: Sixty-one percent responded. Forty-three percent either believed in or were uncertain about alcohol’s purported health benefits. Nevertheless, 86% considered it part of their job to warn the public about alcohol’s carcinogenic effects. Fifty-two percent had at least one alcohol-related policy in place; among that subset, 83% had a policy related to alcohol service during on-site events; 87% had one about reimbursement of that alcohol service. Of concern, only 45% of survey respondents agreed that current literature with regard to alcohol-related cancer risk factors was sufficient to warrant a reconsideration of their alcohol-related policies/practices, and fewer than half have acted on those data. Conclusions: NCI-Designated Cancer Centers can implement policies and change practices now to reduce alcohol intake and the cancer deaths associated with its consumption. Impact: Cancer centers’ leadership in alcohol practices and policies may energize the public to be more thoughtful about their use of alcohol, resulting in long-term reductions in associated cancer risks. See related In the Spotlight, p. 190
Year:
2025
Purpose Cardiotoxicity is a major concern for patients undergoing thoracic radiotherapy. This study compared the predictive power of radiation dose-volume histogram (DVH) parameters and radiomic/dosiomic features of the whole heart (WH) and cardiac substructures for elevated circulating high-sensitivity cardiac troponin T (hs-cTnT), a biomarker for early detection of cardiac adverse events. Methods and Materials A retrospective cohort of 160 patients with non-small cell lung cancer (NSCLC) from a completed prospective trial and a prospective cohort of 57 patients with NSCLC enrolled in an ongoing trial were analyzed. The endpoint was hs-cTnT elevation, indicated by increase of ≥5 ng/L from baseline. An in-house auto-segmentation model delineated 19 cardiac substructures. DVH parameters, radiomic, and dosiomic features were extracted from each patient. A 100-iteration Monte Carlo cross-validation (75%/25% split) was conducted within the retrospective cohort to mitigate random split bias. Logistic regression models using different input combinations were compared, with a model using only clinical factors served as the baseline. Key predictive features were identified using permutation importance during training. Models were validated by hold-out in the prospective cohort to evaluate robustness. Model performance was assessed by area under the receiver operating characteristic curve (AUROC). Results Incidence of hs-cTnT elevation was 31.9% in the retrospective and 29.8% in the prospective cohort. The substructure DVH model achieved the highest predictive performance in cross-validation (mean AUROC 0.71, 95% CI [0.70, 0.73]) and demonstrated greater robustness in hold-out validation compared to WH-based models (AUROC 0.60 vs. ≤0.51). Feature analysis identified the left anterior descending coronary artery V20Gy as the most dominant predictor, with cut-off values ranging from 0.2%-5% using various indices. Conclusions Cardiac substructure DVH parameters have superior predictive power and robustness over WH variables for predicting hs-cTnT elevation in NSCLC radiotherapy, emphasizing the need of using cardiac substructures for cardiotoxicity risk assessment.
Year:
2025
BACKGROUND Digital tools have been shown to play a role in promoting public health interventions. The recommendation that healthcare providers (HCPs) use vaccination-related mobile or web-based applications has contributed to improving vaccine awareness and acceptance among vaccine-eligible individuals. In the United States, the state of Texas, which has one of the lowest HPV vaccination rates, has seen a significant increase in HPV vaccination hesitancy during the COVID-19 pandemic. OBJECTIVE This study examined the association between changes in the HPV vaccine hesitancy observed by HCPs among patients in Texas and the promotion of vaccination-related applications at their healthcare facilities during the COVID-19 pandemic. METHODS A population-based cross-sectional survey administered to HCPs working in Texas between January and April 2021 by The University of Texas MD Anderson Cancer Center was used for this study. We described the observed changes in the HPV vaccination hesitancy reported by the HCPs among patients using descriptive statistics. We conducted a logistic regression analysis to examine the association between the decrease in the HPV vaccine hesitancy observed by HCPs among patients and the promotion of vaccination-related applications at their facility. RESULTS A total of 1283 HCPs completed the survey. Among the 730 HCPs who reported changes in the HPV vaccination hesitancy, 7.0% observed a decrease in the HPV vaccine hesitancy among patients during the COVID-19 pandemic. Among the 576 HCPs who responded to the survey question regarding vaccination-related applications, 20.7% reported that vaccination-related applications were promoted at their facilities. The respondents were predominantly aged 35-54 years (62.6%), females (77.3%), non-Hispanic Whites (50.5%), and working in group practice (39.6%). Compared to HCPs who did not promote vaccination-related applications, those who promoted vaccination-related applications at their healthcare facility had significantly higher odds of observing a decrease in HPV vaccine hesitancy among patients during the COVID-19 pandemic (Adjusted Odds Ratio [aOR]: 2.53, 95% CI: 1.18-5.41). Compared to HCPs who worked at university/teaching hospitals, HCPs working at Federally Qualified Health Clinics (aOR: 8.96, 95% CI: 1.74-46.10), public facilities (aOR: 12.53, 95% CI: 2.01-78.26) and Employed Physician Practices (aOR: 8.63, 95% CI: 1.37-54.39) had significantly higher odds to observe a decrease in the HPV vaccine hesitancy among patients during the COVID-19 pandemic. CONCLUSIONS Our findings demonstrate the benefits of promoting vaccination-related applications at healthcare facilities in areas with high HPV vaccine hesitancy, such as Texas. Digital health interventions could provide a platform for promoting and increasing HPV vaccination uptake in a context of pandemic preparedness. CLINICALTRIAL N/A
Year:
2025
Increasing rates of human papillomavirus (HPV)–driven oropharyngeal cancer (OPC) have largely offset declines in tobacco-associated head and neck squamous cell carcinoma (HNSCC) at non-OPC sites. Host immunity is an important modulator of HPV infection, persistence, and clearance, and also of immune evasion in both virally- and nonvirally-driven cancers. However, the association between collective known cancer-related immune gene variants and HNSCC susceptibility has not been fully characterized. Here, we conducted a genetic association study in the multiethnic Veterans Affairs Million Veteran Program cohort, evaluating 16,050 variants in 1,576 immune genes in 4,012 HNSCC cases (OPC = 1,823; non-OPC = 2,189) and 16,048 matched controls. Significant polymorphisms were further examined in a non-Hispanic white (NHW) validation cohort (OPC = 1,206; non-OPC = 955; controls = 4,507). For overall HNSCC susceptibility in NHWs, we discovered and validated a novel 9q31.1 SMC2 association and replicated the known 6p21.32 HLA-DQ-DR association. Six loci/genes for overall HNSCC susceptibility were selectively enriched in African-Americans (6p21.32 HLA-G, 9q21.33 GAS1, 11q12.2 CD6, 11q23.2 NCAM1/CD56, 17p13.1 CD68, 18q22.2 SOCS6); all 6 genes function in antigen-presenting regulation and T-cell activation. Two additional loci (10q26 DMBT1, 15q22.2 TPM1) were uncovered for non-OPC susceptibility, and three loci (11q24 CRTAM, 16q21 CDH5, 18q12.1 CDH2) were identified for HPV-positive OPC susceptibility. This study underscores the role of immune gene variants in modulating susceptibility for both HPV-driven and non-HPV-driven HNSCC. Additional large studies, particularly in racially diverse populations, are needed to further validate the associations and to help elucidate other potential immune factors and mechanisms that may underlie HNSCC risk. Significance: Several inherited variations in immune system genes are significantly associated with susceptibility to head and neck cancer, which could help improve personalized cancer risk estimates.
Year:
2025
Background We examined the awareness, interest, and information sources relating to cannabis use for cancer management (including management of cancer symptoms and treatment‐related side effects) and determined factors associated with cancer survivors' awareness and interest in learning about cannabis use for cancer management. Methods This was a cross‐sectional study of adult cancer survivors ( N = 1886) receiving treatment at a comprehensive cancer center. Weighted prevalence and multivariable logistic regression analyses were conducted. Results Among cancer survivors, 88% were aware and 60% were interested in learning about cannabis use for cancer management. Common sources of information to learn about cannabis use for cancer management were cancer doctors/nurses (82%), other patients with cancer (27%), websites/blogs (26%), marijuana stores (20%), and family/friends (18%). The odds of being aware of cannabis use for cancer management was lower among male compared to female survivors (adjusted odds ratio [AOR]: 0.61; 95% confidence interval [CI]: 0.41–0.90), non‐Hispanic Blacks compared to non‐Hispanic Whites (AOR: 0.36; 95% CI: 0.21–0.62), and survivors who do not support the legalization of cannabis for medical use compared to those who do (AOR: 0.10; 95% CI: 0.04–0.23). On the other hand, the odds of being interested in cannabis use for cancer management was higher among non‐Hispanic Blacks compared to non‐Hispanic Whites (AOR: 1.65; 95% CI: 1.04–2.62), and among cancer survivors actively undergoing cancer treatment compared to patients on non‐active treatment (AOR: 2.25; 95% CI: 1.74–2.91). Conclusion Awareness of cannabis use for cancer management is high within the cancer survivor population. Results indicated health care providers are leading information source and should receive continued medical education on cannabis‐specific guidelines. Similarly, tailored educational interventions are needed to guide survivors on the benefits and risks of cannabis use for cancer management.
Year:
2024
Background Accurate variant classification and relaying reclassified results to patients is critical for hereditary cancer care delivery. Over a 5‐ to 10‐year period, 6%–15% of variants undergo reclassification. As the frequency of reclassifications increases, the issue of whether, how, when, and which providers should recontact patients becomes important but remains contentious. Methods The authors used inductive thematic analysis to analyze open‐ended comments offered by oncologists and genetic counselors (GCs) from a large national survey. Results Of the 634 oncologists and cancer GCs, 126 (20%) offered substantive free‐text comments. Four thematic areas emerged: 1) ambiguity over professional responsibility to recontact, 2) logistical challenges with recontact, 3) importance of inter‐institutional communication, and 4) suggested solutions. Some oncologists felt that laboratories, not them, are responsible for recontact; others believed that ordering providers/GCs were responsible; GCs readily acknowledged their own responsibility in recontact but added important caveats. Besides the lack of up‐to‐date patient contact information, providers raised unique challenges with recontact: financial instability of laboratories, lack of clinical resources, contacting family members, and accumulating burden of reclassifications. There were numerous calls for developing practice guidelines on prioritizing variants for recontact and discussion on whether duty for recontact may be fulfilled via unidirectional, low touch modalities. Potential solutions to recontact including national databases and patient facing databases were discussed. Conclusions The authors confirm previous themes of stakeholder opinions and add previously unreported contextual details to qualify those themes. Clarifying provider responsibilities through professional guidelines for reclassification and recontact addressing the subthemes identified here will better serve all constituencies.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (53)
Rayjean Hung
University of Toronto
Susan M. Rosenberg
Ben F Love Chair in Cancer Research and professor
Baylor College of Medicine
Jun Xia
assistant professor
Texas A&M University
Yanhong Liu
Associate Professor
Baylor College of Medicine
Charles Darkoh
Professor and R. Palmer Beasley, M.D. & Lu Yu Hwang, M.D. Endowed Chair in Infectious Diseases and Global Health
The University of Texas Health Science Center at Houston
Yun-Chul Hong
Seoul National University College of Medicine
Jennifer Kramer
Baylor College of Medicine
Elizabeth Chiao
Professor
The University of Texas MD Anderson Cancer Center
David Christiani
Harvard University
Wenyaw Chan
-
Adonina Tardon
Coordinating Professor of the Doctoral Program in Medicine and Epidemiology
Universidad Antonio de Nebrija
Qingyi Wei
Professor
-
Christopher I. Amos
Associate Director for Population and Data Science
Baylor College of Medicine
Guoshuai Cai
Assistant Professor
University of Florida
Paula Cuccaro
Associate Professor
The University of Texas Health Science Center at Houston
Donna L. White
Baylor College of Medicine
Melinda Aldrich
Vanderbilt University Medical Center
Vlad Sandulache
Associate Professor
Baylor College of Medicine
Susan Pinney
University of Cincinnati
Stig E. Bojesen
Copenhagen University Hospital
Chao Cheng
Associate Professor
Baylor College of Medicine
Ann G. Schwartz
Wayne State University School of Medicine
Diptasri Mandal
Professor (Tenured)
Louisiana State University Health Sciences Center
Kristen S. Purrington
Associate Professor
Wayne State University School of Medicine
John Field
Professor
University of Liverpool
Guojun Li
The University of Texas MD Anderson Cancer Center
Yohan Bossé
Laval University
Stephanie L. Martch
The University of Texas MD Anderson Cancer Center
Li Jiao
Baylor College of Medicine
Lara Savas
Associate Professor
The University of Texas Health Science Center at Houston
Ryan Sun
Assistant Professor
The University of Texas MD Anderson Cancer Center
Joan Bailey-Wilson
Co-Branch Chief
National Human Genome Research Institute
Philip Lazarus
Professor
University at Buffalo
Andrew Sikora
Professor of Head and Neck Surgery
The University of Texas MD Anderson Cancer Center
Robert J. Volk
Professor
The University of Texas MD Anderson Cancer Center
Matthew Schabath
Program Leader and Senior Member
H Lee Moffitt Cancer Center and Research Institute
Banu K. Arun
The University of Texas MD Anderson Cancer Center
Loic Le Marchand
Professor
University of Hawaii
Monalisa Chandra
Assitant Professor-Health
University of Houston
Iakovos Toumazis
Assistant Professor
The University of Texas MD Anderson Cancer Center
Mikael Johansson
Ass professor
Umea University
Michael Peter Alan Davies
Roy Castle Lung Cancer Foundation Senior Research Fellow
University of Liverpool
Jian-Rong Li
Assistant Professor
Chang Gung University
Jinyoung Byun
Associate Professor
University of New Mexico
Ernest Hawk
The University of Texas MD Anderson Cancer Center
Mattias Johansson
Scientist
International Agency for Research on Cancer
David Hui
The University of Texas MD Anderson Cancer Center
Susanne Arnold
University of Kentucky
Yvonne Mowery
Associate Professor
UPMC Hillman Cancer Center
Geoffrey Liu
The M. Qasim Choksi Chair in Lung Cancer Translational Research
University of Toronto
Ping Yang
Professor
Mayo Clinic Arizona
Chu Chen
Full Member
Fred Hutchinson Cancer Research Center
Jian-Min Yuan
University of Pittsburgh
Make your next move.
Prepare your application
Review drafts before you send them.